| abstract |
The present invention relates to novel compounds, pharmaceutical compositions and methods for treating or preventing microbial infection caused by parasites or bacteria, such as Plasmodium falciparum parasite species or related species of Plasmodium and Mycobacterium tuberculosis bacteria or related species of Mycobacterium. The compounds are α, β-unsaturated analogues of fosmidomycin and can inhibit deoxyxylulose phosphate reductoisomerase (Dxr) in many microbes, such as P. falciparum. |